JP6673837B2 - 白血球動員をブロックするペプチドおよび使用方法 - Google Patents

白血球動員をブロックするペプチドおよび使用方法 Download PDF

Info

Publication number
JP6673837B2
JP6673837B2 JP2016551165A JP2016551165A JP6673837B2 JP 6673837 B2 JP6673837 B2 JP 6673837B2 JP 2016551165 A JP2016551165 A JP 2016551165A JP 2016551165 A JP2016551165 A JP 2016551165A JP 6673837 B2 JP6673837 B2 JP 6673837B2
Authority
JP
Japan
Prior art keywords
peptide
lsalt
amino acid
liver
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016551165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508734A5 (https=
JP2017508734A (ja
Inventor
スティーブン マーク ロビンス，
スティーブン マーク ロビンス，
ドナ エル． サンガー，
ドナ エル． サンガー，
ジェニファー ジョイ ラーン，
ジェニファー ジョイ ラーン，
ポール クーブズ，
ポール クーブズ，
Original Assignee
アーチ キャンサー セラピューティクス，インク
アーチ キャンサー セラピューティクス，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーチ キャンサー セラピューティクス，インク, アーチ キャンサー セラピューティクス，インク filed Critical アーチ キャンサー セラピューティクス，インク
Publication of JP2017508734A publication Critical patent/JP2017508734A/ja
Publication of JP2017508734A5 publication Critical patent/JP2017508734A5/ja
Application granted granted Critical
Publication of JP6673837B2 publication Critical patent/JP6673837B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016551165A 2014-02-13 2015-02-13 白血球動員をブロックするペプチドおよび使用方法 Active JP6673837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939561P 2014-02-13 2014-02-13
US61/939,561 2014-02-13
PCT/CA2015/000078 WO2015120536A1 (en) 2014-02-13 2015-02-13 Peptides that block leukocyte recruitment and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000282A Division JP6994054B2 (ja) 2014-02-13 2020-01-06 白血球動員をブロックするペプチドおよび使用方法

Publications (3)

Publication Number Publication Date
JP2017508734A JP2017508734A (ja) 2017-03-30
JP2017508734A5 JP2017508734A5 (https=) 2018-03-29
JP6673837B2 true JP6673837B2 (ja) 2020-03-25

Family

ID=53774369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016551165A Active JP6673837B2 (ja) 2014-02-13 2015-02-13 白血球動員をブロックするペプチドおよび使用方法
JP2020000282A Active JP6994054B2 (ja) 2014-02-13 2020-01-06 白血球動員をブロックするペプチドおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020000282A Active JP6994054B2 (ja) 2014-02-13 2020-01-06 白血球動員をブロックするペプチドおよび使用方法

Country Status (7)

Country Link
US (3) US9464114B2 (https=)
EP (1) EP3105245B1 (https=)
JP (2) JP6673837B2 (https=)
AU (1) AU2015218198B2 (https=)
CA (1) CA2939266C (https=)
ES (1) ES2891174T3 (https=)
WO (1) WO2015120536A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3057215T3 (en) 2015-08-11 2026-02-26 Arch Biopartners Inc Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5629179A (en) 1995-03-17 1997-05-13 Novagen, Inc. Method and kit for making CDNA library
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
MXPA01010404A (es) * 1999-04-16 2003-07-21 Childrens Medical Center Peptidos moduladores de adhesion y metodos para utilizarlos.
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
WO2006134960A1 (ja) * 2005-06-16 2006-12-21 Shionogi & Co., Ltd. 抗炎症剤のスクリーニング方法
EP3461499A1 (en) * 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
EP2196212A4 (en) * 2007-10-04 2012-01-25 Josai University Corp PREPARATION AND METHOD FOR THE ADMINISTRATION OF A VACCINE AND IONTOPHORESE DEVICE WITH THE PREPARATION
WO2010099084A2 (en) * 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding

Also Published As

Publication number Publication date
JP6994054B2 (ja) 2022-02-03
EP3105245A1 (en) 2016-12-21
JP2017508734A (ja) 2017-03-30
EP3105245B1 (en) 2021-08-18
US20170072006A1 (en) 2017-03-16
CA2939266A1 (en) 2015-08-20
WO2015120536A1 (en) 2015-08-20
ES2891174T3 (es) 2022-01-26
AU2015218198A1 (en) 2016-09-29
US20200038473A1 (en) 2020-02-06
EP3105245A4 (en) 2017-07-26
AU2015218198B2 (en) 2019-07-11
JP2020055873A (ja) 2020-04-09
US20150225459A1 (en) 2015-08-13
US11083773B2 (en) 2021-08-10
US9464114B2 (en) 2016-10-11
CA2939266C (en) 2023-10-03

Similar Documents

Publication Publication Date Title
JP2016515620A5 (https=)
JP2011528566A (ja) アンジオポエチン由来ペプチド
JP6994054B2 (ja) 白血球動員をブロックするペプチドおよび使用方法
KR101958964B1 (ko) 항종양 및 항혈관생성 활성을 갖는 사이클릭 펩타이드
KR20150067228A (ko) 뇌 병태의 치료에서의 안지오텐신
JP2018530590A (ja) 表皮水疱症の処置のための方法及び組成物
JP2024028553A (ja) Ｄｐｅｐ－１結合剤および使用の方法
JP2025121987A (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
CN116710114B (zh) Glp-1/glp-2双重激动剂的药物组合物
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
CN116723850A (zh) Glp-1/glp-2双重激动剂的药物组合物
US20170319648A1 (en) High activity tumour inhibitor and preparation method and use thereof
US20100056441A1 (en) Method for Inhibiting Angiogenesis
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
WO2021152463A1 (ru) Фармацевтическая композиция и способ еe изготовления
HK1228418A1 (en) Yap protein inhibiting polypeptide and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200305

R150 Certificate of patent or registration of utility model

Ref document number: 6673837

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250